老年CHC临床特点及抗病毒治疗策略研究进展

doi:10.3969/j.issn.1672-5069.2018.06.043

Abstract

Abstract: Hepatitis C virus（HCV） infection is of concern in elderly patients because the proportion of patients with prolonged duration of infection increases gradually,which might be associated with an increased risk of HCV infection-associated liver diseases,includingcirrhosis and hepatocellular carcinoma. The patients with chronic hepatitis C（CHC） at this ages tends to be accompanied with underlying diseases,such as malignancy,kidney disease,diabetes,cardiovascular disease,and neurocognitive impairment. The efficacy of new direct-acting antiviral agents （DAA） for the treatment of elderly patients with CHC is still under investigation,and the safety needs further observations.

Key words: Hepatitis C, Direct-acting antiviral agents, Liver cirrhosis, Hepatocellular carcinoma, Elderly

Ji Xiaoqin, Gong Jian.. Clinical features and antiviral treatment of elderly patients with chronic hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 995-998.

References

[1] Liu Z,Yang Q,Shi O,et al.The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014:An observational population-based study. J Viral Hepat,2018,20:1-12.
[2] Armstrong GL,Wasley A,Simard EP,et al.The prevalence of hepatitis C virus infection in the United States,1999 through 2002. Ann Intern Med,2006,144(10):705-714.
[3] Rein DB,Smith BD,Wittenborn JS,et al.The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med,2012,156(4):263-270.
[4] Denniston MM,Jiles RB,Drobeniuc J,et al.Chronic hepatitis C virus infection in the United States,National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med,2014,160(5):293-300.
[5] Davis GL,Albright JE,Cook SF,et al.Projecting future complications of chronic hepatitis C in the United States. Liver Transpl,2003,9(4):331-338.
[6] Tong MJ,el-Farra NS,Reikes AR,et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med,1995,332(22):1463-1466.
[7] Minola E,Prati D,Suter F,et al.Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood,2002,99(12):4588-4591.
[8] Chou JP,Effros RB.T cell replicative senescence in human aging. Curr Pharm Des,2013,19(9):1680-1698.
[9] Mangia A,Ripoli M.Insulin resistance,steatosis and hepatitis C virus. Hepatol Int,2013,7(Suppl 2):782-789.
[10] Younossi ZM,Stepanova M,Nader F,et al.Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther,2013,37(6):647-652.
[11] Mehta SH,Brancati FL,Strathdee SA,et al.Hepatitis C virus infection and incident type 2 diabetes. Hepatology,2003,38(1):50-56.
[12] Mehta SH,Strathdee SA,Thomas DL.Association between hepatitis C virus infection and diabetes mellitus. Epidemiol Rev,2001,23(2):302-312.
[13] Kawaguchi Y,Mizuta T.Interaction between hepatitis C virus and metabolic factors. World J Gastroenterol,2014,20(11):2888-2901.
[14] Kawaguchi T,Ide T,Taniguchi E,et al.Clearance of HCV improves insulin resistance,beta-cell function,and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol,2007,102(3):570-576.
[15] Mahale P,Torres HA,Kramer JR,et al.Hepatitis C virus infection and the risk of cancer among elderly US adults:a registry-based case-control study. Cancer,2017,123(7):1202-1211.
[16] Zignego AL,Giannini C,Gragnani L.HCV and lymphoproliferation. Clin Dev Immunol,2012,2012:980942.
[17] Oliveira CP,Kappel CR,Siqueira ER,et al.Effects of hepatitis C virus on cardiovascular risk in infected patients:a comparative study. Int J Cardiol,2013,164(2):221-226.
[18] Boddi M,Abbate R,Chellini B,et al.Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol,2010,47(1):72-75.
[19] Hassoun Z,Willems B,Deslauriers J,et al.Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci,2002,47(12):2674-2781.
[20] Forton DM. Altered monoaminergic transporter binding in hepatitis C related cerebral dysfunction:a neuroimmunologial condition Gut,2006,55(11):1535-1537.
[21] Casato M,Saadoun D,Marchetti A,et al.Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis:a multicenter case-control study using magnetic resonance imaging and neuropsychological tests. J Rheumatol,2005,32(3):484-488.
[22] Weissenborn K,Ennen JC,Bokemeyer M,et al.Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut,2006,55(11):1624-1630.
[23] Fontana RJ,Bieliauskas LA,Back-Madruga C,et al.Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol,2005,43(4):614-622.
[24] Laskus T,Radkowski M,Bednarska A,et al.Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol,2002,76(19):10064-10068.
[25] Paulino AD,Ubhi K,Rockenstein E,et al.Neurotoxic effects of the HCV core protein are mediated by sustained activation of ERK via TLR2 signaling. J Neurovirol,2011,17(4):327-340.
[26] Molnar MZ,Alhourani HM,Wall BM,et al.Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology,2015,61(5):1495-1502.
[27] Fischer MJ,Wyatt CM,Gordon K,et al.Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr,2010,53(2):222-226.
[28] Sato I,Shimbo T,Kawasaki Y,et al.Efficacy and safety of interferon treatment in elderly patients with chronic hepatitis C in Japan:a retrospective study using the Japanese Interferon Database. Hepatol Res,2015,45(8):829-836.
[29] El-Serag HB,Kramer J,Duan Z,et al.Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat,2016,23(9):687-696.
[30] Ioannou GN,Beste LA,Chang MF,et al. Effectiveness of sofosbuvir,ledipasvir/sofosbuvir,or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology,2016,151(3):457-471.e5.
[31] Saab S,Park SH,Mizokami M,et al.Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology,2016,63(4):1112-1119.
[32] Su F,Beste LA,Green PK,et al.Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients:a real-world study of 17 487 patients. Eur J Gastroenterol Hepatol,2017,29(6):686-693.
[33] El-Serag HB,Kanwal F,Richardson P,et al.Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology,2016,64(1):130-137.
[34] Thein HH,Maruff P,Krahn MD,et al.Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med,2007,8(8):520-528.

Clinical features and antiviral treatment of elderly patients with chronic hepatitis C

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[3]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[4]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[5]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[6]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[7]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[8]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.
[9]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[10]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[11]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[12]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[13]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[14]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[15]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.